ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
34 announcements
Alivus Life Sciences signed a Shareholders' Agreement with IQGEN-X Pharma and its continuing shareholders. It governs inter se rights after the company's 76% IQGEN-X stake purchase.
Nirma Limited, a promoter of Alivus Life Sciences, sold 36,80,000 shares (2.99%) in the open market on 6 November 2026. Promoter holding falls from 74.73% to 71.74%.
Alivus reported strong revenue growth driven by new products and CDMO traction, though margins were inflated by one-time income.
Alivus Life Sciences allotted 1,95,833 equity shares to an employee who exercised ESOP options under its 2021 scheme. Paid-up capital rises to Rs. 24.59 Crore.
Q2 FY27 revenue ₹6,820 Mn (+16.0% YoY), EBITDA ₹2,851 Mn (41.8% margin), PAT ₹1,968 Mn (+51.3% YoY). Non-GPL growth and CDMO pickup drove results.
Alivus Life Sciences reported Q2FY27 revenue of Rs. 6,820 Mn (up 16.0% YoY) and PAT of Rs. 1,968 Mn in a press release. Investors see record EBITDA margins of 41.8% and capex progress at Solapur and Taloja.
Alivus Life Sciences Ltd reported revenue from operations of ₹682 Cr (+16.0% YoY) and net profit of ₹196.7 Cr (+51.3% YoY) for Q2 FY27.
Alivus Life Sciences Ltd has scheduled a Board Meeting on October 29, 2026, to consider and approve its unaudited financial results for the period ended September 30, 2026.
The company filed its quarterly shareholding pattern for the period ended September 30, 2026, as per regulatory requirements.
Alivus Life Sciences Limited received a GST order for FY 2020-22 involving a tax demand and penalty of Rs. 0.51 Crore. The company is currently assessing an appeal.
Alivus Life Sciences acquired a 9.21% stake in Torrent Urja 19 Private Limited for Rs. 14.04 Crore. The investment supports its renewable energy and carbon neutrality goals.
Alivus Life Sciences incorporated a wholly owned pharma subsidiary in Brazil. The company subscribes up to R$500,000 (₹0.90 Cr) for 100% of the new entity.
Alivus Life Sciences Limited successfully conducted its 15th Annual General Meeting on September 8, 2026. All resolutions proposed in the AGM notice were passed with requisite majority.
Alivus Life Sciences Limited will acquire a 76% stake in IQGEN-X Pharma Private Limited for approximately ₹9.12 Crore. This strategic acquisition enhances the company's CDMO solution offerings.
Alivus Life Sciences submitted its Business Responsibility & Sustainability Report for FY 2025-26, detailing operational metrics, employee statistics, and sustainability performance.
Alivus Life Sciences Limited has filed its Integrated Annual Report for FY 2025-26 in compliance with Regulation 34(1) of SEBI Listing Regulations.
Alivus Life Sciences will hold its 15th AGM on September 8, 2026. The company fixed September 1, 2026, as the record date for a Rs. 5.00 dividend.
Alivus reported strong Q1 FY27 results with 6.4% revenue growth, masking a massive 52.6% decline in its legacy GPL business through high-margin non-GPL growth and operational efficiencies.
Alivus Life Sciences allotted 32,000 equity shares under its Employee Stock Option Scheme, 2021. This increases the company's total paid-up share capital.
Alivus Life Sciences delivered strong Q1FY27 performance with revenue at ₹6,404 Mn and EBITDA margins expanding to 36.6%. The company is pivoting towards Non-GPL segments and CDMO growth.
Alivus Life Sciences reported Q1 FY27 financial highlights with revenue growing 6.4% YoY to Rs. 6,404 million and PAT rising 31.8% YoY.
Alivus Life Sciences Ltd reported revenue from operations of ₹640.4 Cr (+6.4% YoY) and net profit of ₹160.1 Cr (+31.8% YoY) for Q1 FY27.
Alivus Life Sciences scheduled a board meeting for July 30, 2026. The meeting aims to approve unaudited financial results for the quarter ended June 30, 2026.
Alivus (ex-Glenmark Life Sciences) reported strong Q4FY26 results with record 33.6% EBITDA margins, driven by non-GPL growth (71% of business) and CDMO recovery.
Alivus (formerly Glenmark Life Sciences) delivered record FY26 EBITDA margins of 33.6%, shifting successfully from GPL dependency to a more profitable non-GPL segment despite a major plant fire and global headwinds.
Alivus reported Q4FY26 revenue of ₹6,891 Mn (6.1% YoY) and PAT of ₹1,627 Mn (14.7% YoY). Strategy shifts from Glenmark-heavy mix to non-GPL (71% of revenue) under Nirma ownership.
Alivus Life Sciences reported FY26 revenue growth of 6.9% YoY and EBITDA margins of 33.6%. The company also announced a new R&D centre in Taloja.
Alivus Life Sciences allotted 3,100 equity shares following employee stock option exercises. This marginal expansion of paid-up capital reflects the ongoing implementation of its ESOP scheme.
Alivus Life Sciences Ltd reported revenue from operations of ₹689.1 Cr (+6.1% YoY) and net profit of ₹162.7 Cr (+14.7% YoY) for Q4 FY26.
Alivus Life Sciences approved FY2025-26 audited results and recommended a ₹5 per share final dividend. The company reported annual revenue from operations of ₹2,551.83 Crore.